4 minute read
Aug. 26, 2022

CHF-6366: a Muscarinic Antagonist and β2 Agonist (MABA) as an Inhaled Treatment for Respiratory Diseases


inhaled mAChRs and ADRB2 agonist Ph. I/II candidate in Asthma and COPD discontinued soft drug design from previously disclosed lead MABA J. Med. Chem., July 28, 2022 Chiesi Farmaceutici S.p.A, Parma, IT

Drug Hunter Team

CHF-6366 (Chiesi Farmaceutici S.p.A) is a muscarinic antagonist and β2 agonist (MABA) being developed as an inhaled treatment for respiratory diseases. Muscarinic antagonists and β2 agonists both act to inhibit bronchoconstriction, but through different mechanisms, making the combination of both agents a desirable strategy for [...]



Other molecules you may be interested in